ArticleJGH open : an open access journal of gastroenterology and hepatology2025
Clinical Outcomes of Endoscopic Submucosal Dissection for Early Gastric Cancer Patients With Concurrent Advanced Malignancies With Expected Poor Prognosis.
Article in JGH open : an open access journal of gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Predicting post-ESD bleeding in elderly patients with early gastrointestinal cancer: an explainable model based on endoscopic features.Frontiers in medicine · 2026Article
- Clinical Outcomes of Endoscopic Submucosal Dissection for Early Gastric Cancer Patients With Concurrent Advanced Malignancies With Expected Poor Prognosis.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Despite improved outcomes for malignant tumors, evidence regarding the management of patients with multiple malignancies remains limited. We aimed to evaluate the clinical outcomes and prognosis of patients undergoing endoscopic submucosal dissection (ESD) for early gastric cancer (EGC) complicated by advanced malignancies in other organs with a poor prognosis. Methods and Results: We retrospectively reviewed 3703 gastric cancer patients who underwent ESD at our hospital (2005-2022), focusing on those with advanced extra-gastric malignancies with a 5-year survival rate of < 50%. ESD was performed for local tumor control based on patient preference when feasible, including lesions meeting standard, expanded, or relative indications where curative resection was unachievable. Clinicopathological characteristics and outcomes were analyzed. Twenty-six patients met the inclusion criteria. En bloc resection was achieved in all cases (100%), with curative and non-curative resection in 16 (62%) and 10 (38%) cases, respectively. None of the 10 patients with non-curative resection exhibited lymphovascular invasion or GC recurrence. Complications included delayed bleeding, perforation, and pneumonia, each in one patient (4%), all leading to disseminated intravascular coagulation (DIC) and death within 30 days post-ESD. Notably, no complications were reported after 2010. Eleven patients died from advanced malignant tumors, with no GC recurrences observed during follow-up in surviving patients. Conclusions: Recently, no severe complications have been observed with ESD. Although ESD for local control in EGC with concurrent advanced extra-gastric malignancies may be acceptable, the risk of severe complications, including DIC, remains. Therefore, careful patient selection and thorough informed consent are essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.